EUVIMEDEUVIMED entdecken
Crossref

Plozasiran (Redemplo) for Familial Chylomicronemia Syndrome

The Medical Letter on Drugs and Therapeutics · 13.04.2026 · 68 (1752) · 68-62

DOI: 10.58347/tml.2026.1752c ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 13.04.2026. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Plozasiran (Redemplo – Arrowhead), an apolipoprotein C-III (apoC-III)-directed small interfering ribonucleic acid (siRNA), has been approved by the FDA to reduce triglyceride levels in adults with familial chylomicronemia syndrome (FCS). It is the second drug to be approved in the US for this indication; the apoC-III-directed antisense oligonucleotide olezarsen (Tryngolza) was approved in 2024.

Schlagwörter

Stichwörter der Autor:innen

RedemploTryngolzaadverse effectsdosageefficacyfamilial chylomicronemia syndromelactationolezarsenplozasiranpregnancysafety

Zitieren

APA

(2026). Plozasiran (Redemplo) for Familial Chylomicronemia Syndrome. The Medical Letter on Drugs and Therapeutics, 68(1752), 68-62. https://doi.org/10.58347/tml.2026.1752c

Vancouver

Plozasiran (Redemplo) for Familial Chylomicronemia Syndrome. The Medical Letter on Drugs and Therapeutics. 2026;68(1752):68-62. doi:10.58347/tml.2026.1752c

BibTeX
@article{euvimed2026,
  title = {Plozasiran (Redemplo) for Familial Chylomicronemia Syndrome},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2026},
  volume = {68},
  number = {1752},
  pages = {68--62},
  doi = {10.58347/tml.2026.1752c}
}
Kostenlos starten →